Safety and efficacy of nab paclitaxel in the treatment of patients with breast cancer

Breast Cancer: Basic and Clinical Research

Volumn 5, Issue 1, 2011, Pages 53-65

  Vishnu, Prakash ^a   Roy, Vivek ^a  

^a MAYO CLINIC   (United States)

Author keywords

Metastatic breast cancer; Nab paclitaxel; Nab technology; Paclitaxel; Taxanes

Indexed keywords

ABI 008; ALBUMIN; ASPARTATE AMINOTRANSFERASE; AZACITIDINE; BEVACIZUMAB; BILIRUBIN; CAPECITABINE; CAVEOLIN 1; CREMOPHOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; IMIQUIMOD; LAPATINIB; NANOMETER ALBUMIN BOUND PACLITAXEL; NANOPARTICLE; NAVELBINE; OSTEONECTIN; PACLITAXEL; PEMETREXED; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SOLVENT; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ADJUVANT THERAPY; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ELECTROCARDIOGRAM; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART ARREST; HUMAN; INFECTION; KERATOPATHY; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MITOSIS INHIBITION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NANOTECHNOLOGY; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PREMEDICATION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOSENSITIZATION; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; SOLVENT EFFECT; STOMATITIS; SUPERFICIAL KERATOPATHY; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; VISUAL IMPAIRMENT;

EID: 79958100231     PISSN: 11782234     EISSN: None     Source Type: Journal    
DOI: 10.4137/BCBCR.S5857     Document Type: Review

References (37)

1. Kataja V, Castiglione M. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow up. Ann Oncol. May 2009;20 Suppl 4:10-14.
2. Kataja V, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow up. Ann Oncol. May 2008;19 Suppl 2:ii11-ii13.
3. NCCN Clinical Practice Guidelines in Oncology / Breast Cancer v 2.2011. 2011; http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed 12/10/2010.
4. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane based combinations as adjuvant chemotherapy of early breast cancer: a meta analysis of randomized trials. J Clin Oncol. Jan 1 2008;26(1):44-53.
5. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Research. Apr 1 1999;59(7):1454-1457.
6. Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clinical Pharmacokinetics. 2003;42(7):665-685.
7. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. Mar 1999;17(3):1061-70.
8. Van Zuylen L, Karlsson MO, Verweij J, et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemotherapy and Pharmacology. Apr 2001;47(4):309-18.
9. Winer EP, Berry DA, Woolf S, et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. Jun 1 2004;22(11):2061-2068.
10. Seidman AD. Will weekly work? Seems to be so. J Clin Oncol. Sep 1 2005;23(25):5873-4.
11. NCI Alliance for Nanotechonology in Cancer. 2010; http://nano.cancer.gov/learn/understanding. Accessed 12/10/2010.
12. Desai NP, Trieu V, Hwang LY, Wu R, Soon Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin bound (nab) paclitaxel versus polysorbate based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anti cancer Drugs. Oct 2008;19(9):899-909.
13. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor free, albumin bound paclitaxel, ABI 007, compared with cremophor based paclitaxel. Clin Cancer Res. Feb 15 2006;12(4):1317-1324.
14. Zhou Q, Ching AK, Leung WK, et al. Novel therapeutic potential in targeting microtubules by nanoparticle albumin bound paclitaxel in hepatocellular carcinoma. Int J Oncol. Mar 2011;38(3):721-731.
15. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI 007, a Cremophor free, protein stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. May 2002;8(5):1038-1044.
16. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI 007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. Nov 1 2005;23(31): 7785-7793.
17. Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover phar macokinetic study of solvent based paclitaxel and nab paclitaxel. Clin Cancer Res. Jul 1 2008;14(13):4200-4205.
18. Stinchcombe TE, Socinski MA, Walko CM, et al. Phase I and pharmacoki netic trial of carboplatin and albumin bound paclitaxel, ABI 007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemotherapy and Pharmacology. Oct 2007;60(5):759-766.
19. Chien AJ, Illi JA, Ko AH, et al. A phase I study of a 2 day lapatinib chemosensi tization pulse preceding nanoparticle albumin bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. Sep 1 2009;15(17):5569-5575.
20. Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI 007, an albumin bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. Sep 1 2005;23(25):6019-6026.
21. Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. Dec 2007;7(11):850-856.
22. Mirtsching B, Cosgriff T, Harker G, Keaton M, Chidiac T, Min M. A Phase II study of weekly nanoparticle albumin bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clin Breast Cancer. Jan 11 2011:1-8.
23. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM. Phase II trial of weekly nab (nanoparticle albumin bound) paclitaxel (nab paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol. Mar 2009;20(3):449-53.
24. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression free survival with nab paclitaxel compared with docetaxel as first line therapy for metastatic breast cancer. J Clin Oncol. Aug 1 2009;27(22): 3611-3619.
25. Robert N, Krekow L, Stokoe C, Clawson A, Iglesias J, O'Shaughnessy J. Adjuvant dose dense doxorubicin plus cyclophosphamide followed by dose dense nab paclitaxel is safe in women with early stage breast cancer: a pilot study. Breast Cancer Research and Treatment. Jan 2011;125(1): 115-120.
26. Robidoux A, Buzdar AU, Quinaux E, et al. a phase II neoadjuvant trial of sequential nanoparticle albumin bound paclitaxel followed by 5 fuorouracil/ epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer. Feb 1 2010;10(1):81-86.
27. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin bound paclitaxel compared with polyethylated castor oil based paclitaxel in women with breast cancer. J Clin Oncol. Nov 1 2005;23(31): 7794-803.
28. Guan Z, Feng F, Li QL, et al. Randomized study comparing nab paclitaxel with solvent based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). Paper presented at: American Society of Clinical Oncology Annual Meeting June 20, 2007; Chicago, IL, USA.
29. ABRAXANE Healthcare Professional Prescribing Information. September 2009; http://www.abraxane.com/professional/PDF/Abraxane_Healthcare_Professional_Prescribing_Information.pdf. Accessed 01/12/2010.
30. Dranitsaris G, Coleman R, Gradishar W. nab Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Research and Treatment. Jun 3 2009.
31. Desai N, Trieu V, Damascelli B, Soon Shiong P. SPARC expression correlates with tumor response to albumin bound paclitaxel in head and neck cancer patients. Translational Oncology. May 2009;2(2):59-64.
32. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor free, albumin bound particle form of paclitaxel for the treatment of advanced non small cell lung cancer. Ann Oncol. Aug 2006;17(8):1263-1268.
33. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130 nm albumin bound paclitaxel as initial chemotherapy in patients with stage IV non small cell lung cancer. J Clin Oncol. Feb 1 2008;26(4): 639-643.
34. Socinski MA, Bondarenko NA, Karaseva MA, et al. Results of a randomized, phase III trial of nab paclitaxel (nab P) and carboplatin (C) compared with cremophor based paclitaxel (P) and carboplatin as first line therapy in advanced non small cell lung cancer (NSCLC). Paper presented at: ASCO Annual Meeting 2010; June 2010; Chicago.
35. Wiedenmann N, Valdecanas D, Hunter N, et al. 130 nm albumin bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res. Mar 15 2007;13(6):1868-1874.
36. ClincalTrials.gov. 2010; www.clinicaltrials.gov. Accessed 12/10/2010.
37. ABRAXANE Healthcare Professional Prescribing Information. 2009; http://www.abraxane.com/professional/PDF/Abraxane_Healthcare_Professional_Prescribing_Information.pdf. Accessed 12/10/2010.